Castration-Resistant Prostate Cancer
Author and Disclosure Information [Show]

Medical College of Wisconsin, Milwaukee, WI

Question 1 of 5

An 89-year-old man was diagnosed with prostate cancer 7 years ago and is status post radical retropubic prostatectomy. At the time of diagnosis, he had Gleason 3 + 4 = 7 disease with perineural invasion but negative margins on resection, no disease outside of the prostate on imaging, and an initial prostate-specific antigen (PSA) level of 5.2 ng/mL. Following surgery, PSA became undetectable, but began to rise 2 years after surgery. The patient then received definitive radiation therapy to the prostate bed with an initial downtrend in PSA. However, 2 years after receiving radiation, his PSA once again began to rise. Restaging scans were negative for metastatic disease. He was started on leuprolide injections and bicalutamide, and his PSA subsequently dropped. However, after 8 months of therapy, the PSA began to rise from a nadir of 0.9 ng/mL to 1.3 ng/mL in 12 months. In the next 12 months, the PSA increased to 2.1 ng/mL. Restaging scans are negative for metastatic disease, and his serum testosterone level is 3 ng/dL. The patient has no urinary symptoms.

What is the next most appropriate step in management?

Discontinue leuprolide/bicalutamide and start docetaxel and prednisone

Discontinue leuprolide/bicalutamide and start sipuleucel-T

Discontinue leuprolide/bicalutamide and start radium 223

Discontinue leuprolide/bicalutamide and start abiraterone

Discontinue bicalutamide and continue leuprolide

Hospital Physician: Hematology/Oncology. 2019 April;14(4)

This quiz is not accredited for CME.

More from Board Review Questions: Hematology/Oncology


Autoimmune Hemolytic Anemia
Gastrointestinal Stromal Tumors
Testicular Cancer
Management of Advanced Melanoma
Transfusion Reactions (part 2)
Transfusion Reactions (part 1)
Plasma Cell Disorders (part 3)
Plasma Cell Disorders (part 2)
Chronic Myeloid Leukemia
Aplastic Anemia
Small Cell Lung Cancer
Management of Metastatic Gastric Cancer
Transfusion Medicine
Acute Myeloid Leukemia
Management of Colorectal Cancer in Older Adults
Urothelial Carcinoma: Muscle-Invasive and Metastatic Disease
Pancreatic Adenocarcinoma: Advanced Unresectable and Metastatic Disease
HER2-Positive Breast Cancer
Aggressive B-Cell Non-Hodgkin Lymphoma
Von Willebrand Disease: Assessment and Diagnostic Testing
Von Willebrand Disease: Clinical Management
Pancreatic Adenocarcinoma: Neoadjuvant and Adjuvant Treatment
Late Pulmonary Complications After Hematopoietic Stem Cell Transplantation
Polycythemia Vera and Essential Thrombocythemia: Current Management
Treatment of Biliary Tract Cancers
Early Pulmonary Complications After Hematopoietic Stem Cell Transplantation
Hairy Cell Leukemia
Genomic Testing in Women with Early-Stage Hormone Receptor–Positive, HER2-Negative Breast Cancer
Immune Thrombocytopenia
Cancer-Related Fatigue
Disseminated Intravascular Coagulation
Advanced Stage and Relapsed/Refractory Hodgkin Lymphoma
Adjuvant Chemotherapy for Colon Cancer
Molecular Markers and Targeted Therapies in the Management of Non-Small Cell Lung Cancer
Metastatic Cutaneous Melanoma: Targeted Therapy and Immunotherapy
Thrombosis in Pregnancy
Locally Advanced Pancreatic Cancer
Early-Stage Hodgkin Lymphoma
Neoadjuvant and Adjuvant Therapy for Gastric Cancer
Hemophilia A and B
Mantle Cell Lymphoma
Soft Tissue Sarcoma
Sickle Cell Disease
Renal Cell Carcinoma
Management of Locally Advanced Rectal Adenocarcinoma
Adjuvant Systemic Therapy for Early-Stage Breast Cancer
Chronic Myeloid Leukemia
Plasma Cell Disorders
Myelodysplastic Syndromes
Acute and Chronic Graft-versus-Host Disease